Linzhong Li – Certara

Predicting the Concentration of PARP Inhibitors in Human Tumor Tissue Using PBPK Modeling

Topics:

Evaluating the efficiency of payload delivery by ADCs using a minimal PBPK model

Topics:

Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the Most Influential Parameters of a Minimal PBPK Model of Midazolam

Topics:

Development of Paclitaxel PBPK Model to Predict Tumour Concentration in Cancer Patients

Topics:

Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model

Topics:

Application of Global Sensitivity Analysis Methods to Determine the Most Influential Parameters of a Minimal PBPK Model of Quinidine

Topics:

A Whole Body Physiologically-based Pharmacokinetic Model for Antibody Drug Conjugates—Model Development and Validation in Rat

Topics:

Mechanistic Modeling of Antibody Drug Conjugate Pharmacokinetics

Posted by Linzhong Li

on Apr 20, 2016 12:06:09 PM

Antibody Drug Conjugates (ADCs) are constructed by attaching a small molecule drug to an antibody via a linker. The antibody selectively targets tumor cells and releases the cytotoxic drug within the cells to kill cancerous cells while sparing healthy tissue. Although some ADCs have been approved, many unanswered questions remain, such as drug-drug interactions (DDIs) and […]

Topics: PBPK Modeling & Simulation

A Bottom-up Whole-body Physiologically-based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins

Topics:

A Mechanistic Minimal PBPK Model to Predict Distribution and Subcutaneous Absorption of Therapeutic Proteins

Topics:

A Minimal Physiologically-based Pharmacokinetic Model of IgG: Impact of Inclusion of 2:1 FcRn IgG Binding Stoichiometry and a Proportion of CL That Is Independent of FcRn Binding

Topics:

Emerging Covariates on the Pharmacokinetics of Monoclonal Antibodies: Do Current PBPK Models Account for the Significant Covariates Identified in PopPK Studies?

Topics:

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically-based Pharmacokinetic FcRn Model

Although advantages of physiologically based pharmacokinetic models (PBPK) are now well established, PBPK models that are linked to pharmacodynamic (PD) models to predict pharmacokinetics (PK), PD, and efficacy of monoclonal antibodies (mAbs) in humans are uncommon. The aim of this study was to develop a PD model that could be linked to a physiologically based mechanistic FcRn model to predict PK, PD, and efficacy of efalizumab. The mechanistic FcRn model for mAbs with target-mediated drug disposition within […]

Topics:

A Mechanistic PBPK Model to Predict Subcutaneous Absorption of Therapeutic Proteins and Monoclonal Antibodies

Topics:

Modeling the Binding Kinetics of Antibody, Antigen, and FcyRs

Topics:

Simulation of Monoclonal Antibody Pharmacokinetics in Humans Using a Minimal Physiologically-based Model

Compared to small chemical molecules, antibodies and Fc-containing derivatives (mAbs) have unique pharmacokinetic behavior characterized by relatively poor cellular permeability, minimal renal filtration, binding to FcRn, target-mediated drug disposition, and disposition via lymph. A minimal physiologically based pharmacokinetic (PBPK) model to describe the pharmacokinetics of mAbs in humans was developed. Within the model, the body is divided into three physiological compartments; plasma, a single tissue compartment and lymph. The […]

Topics: